Mitsubishi UFJ Asset Management UK Ltd. Has $1.79 Million Stake in Integra Lifesciences Holdings Corp (IART)
Mitsubishi UFJ Asset Management UK Ltd. grew its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 83.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,400 shares of the life sciences company’s stock after buying an additional 17,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Integra Lifesciences were worth $1,789,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in IART. Capital Research Global Investors increased its position in shares of Integra Lifesciences by 227.0% during the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after buying an additional 2,705,488 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Integra Lifesciences during the second quarter valued at about $112,068,000. Koch Industries Inc. increased its position in shares of Integra Lifesciences by 12,623.4% during the second quarter. Koch Industries Inc. now owns 754,880 shares of the life sciences company’s stock valued at $741,000 after buying an additional 748,947 shares during the period. Orbimed Advisors LLC increased its position in shares of Integra Lifesciences by 155.5% in the third quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after purchasing an additional 664,000 shares during the last quarter. Finally, FMR LLC increased its position in shares of Integra Lifesciences by 6.2% in the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock worth $440,690,000 after purchasing an additional 468,678 shares during the last quarter. Hedge funds and other institutional investors own 87.58% of the company’s stock.
In related news, Director Barbara B. Hill acquired 10,768 shares of the company’s stock in a transaction dated Tuesday, October 31st. The stock was purchased at an average price of $46.66 per share, with a total value of $502,434.88. Following the completion of the purchase, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the sale, the vice president now directly owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. Corporate insiders own 21.50% of the company’s stock.
Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up $0.19 during trading hours on Friday, hitting $50.18. The stock had a trading volume of 522,400 shares, compared to its average volume of 608,383. The stock has a market capitalization of $3,923.09, a price-to-earnings ratio of 82.26, a PEG ratio of 1.61 and a beta of 0.65. Integra Lifesciences Holdings Corp has a 52-week low of $40.51 and a 52-week high of $56.42. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The company had revenue of $278.83 million for the quarter, compared to analysts’ expectations of $286.00 million. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $0.93 EPS. equities research analysts forecast that Integra Lifesciences Holdings Corp will post 1.85 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://theolympiareport.com/2018/01/19/mitsubishi-ufj-asset-management-uk-ltd-has-1-79-million-stake-in-integra-lifesciences-holdings-corp-iart.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.